2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaçi D, Strober B, Gordon K, Foley P, Gooderham M, Morita A, Papp K, Puig L, Menter M, Colombo M, Elbez Y, Kisa R, Ye J, Napoli A, Wei L, Banerjee S, Merola J, Gottlieb A. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology And Therapy 2022, 12: 495-510. PMID: 35025062, PMCID: PMC8850503, DOI: 10.1007/s13555-021-00649-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSevere plaque psoriasisPhase 2 trialPlaque psoriasisStatic Physician's Global AssessmentBody surface area involvementGlobal assessmentPhase 2 clinical trialLife outcomesComplete skin clearanceMethodsPost-hoc analysisPhysician global assessmentSurface area involvementNew oral therapiesLife Quality IndexMost efficacy measuresPromising new oral therapyGreater improvementSkin clearanceSevere psoriasisOral therapyPsoriasis AreaInvestigator assessmentClinical outcomesWeek 12
2013
Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary
Strober B, Nyirady J, Mallya U, Guettner A, Papavassilis C, Gottlieb A, Elewski B, Turner-Bowker D, Shields A, Gwaltney C, Lebwohl M. Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary. Value In Health 2013, 16: 1014-1022. PMID: 24041351, DOI: 10.1016/j.jval.2013.07.002.Peer-Reviewed Original ResearchConceptsSymptom diaryClinical trialsSevere chronic plaque-type psoriasisChronic plaque-type psoriasisGlobal assessmentDermatology Life Quality IndexPhase 2 clinical trialChronic plaque psoriasisInvestigator's Global AssessmentPatient Global ImpressionPlaque-type psoriasisFuture clinical trialsLife Quality IndexPsychometric propertiesPlaque psoriasisPsoriasis AreaWeek 12Global ImpressionResponder definitionAdult outpatientsNew patientsItem-level psychometric propertiesStudy weekDiary assessmentsDiary items